Prognostic value of selected chromosomal abnormalities in
multiple myeloma patients treated by thalidomide

D 2007

Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK et. al.

Základní údaje

Originální název

Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

Název česky

Prognostický význam vybraných chromozomálních aberací u pacientů s mnohočetným myelomem léčených thalidomidem

Autoři

ZAORALOVÁ, Romana (203 Česká republika), Henrieta GREŠLIKOVÁ (703 Slovensko), Hana FILKOVÁ (203 Česká republika), Pavel NĚMEC (203 Česká republika), Petr KUGLÍK (203 Česká republika, garant), Alexandra OLTOVÁ (203 Česká republika), Luděk POUR (203 Česká republika), Zdeněk ADAM (203 Česká republika), Andrea KŘIVANOVÁ (203 Česká republika), Marta KREJČÍ (203 Česká republika) a Roman HÁJEK (203 Česká republika)

Vydání

Vol. 92(s2). Pavia (Italy), Haematologica, s. 170-170, 2007

Nakladatel

Ferrata-Storti foundation

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

Genetika a molekulární biologie

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.516

Kód RIV

RIV/00216224:14110/07:00022773

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000247425800349

Klíčová slova anglicky

Multiple myeloma; thalidomide; cIg FISH

Štítky

cIg FISH, multiple myeloma, Thalidomide

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 3. 2009 11:05, Mgr. Pavel Němec, Ph.D.

Anotace

ORIG CZ

V originále

The aim of this prospective study is to investigate if Thalidomide is able to antagonize the impact of cytogenetic negative prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of 13q14 (RB), deletion of 17p13 (p53), amplification of CKS1B gene (1q21) and translocation t(4;14). Material and Methods: For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labelling methodology. This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-k or anti-l) and to detect chromosomal abnormalities by fluorescence in situ hybridization (cIg-FISH). Overall characteristics of up-to-date set of 24 patients (pts.): median age 65,0 years (range 48,3-83,3). 66% (16/24 pts.) in stage IIIA, 29% (7/24 pts.) in stage IIA and 1 patient in IIIB. 75% (16/24 pts.) were in first relapse; the others were in second relapse. Preliminary Results: Cytogenetic findings: Deletion of 13q14 was detected in 62% (13/21) pts., t(4;14) in 66% (14/21) pts., deletion of 17p13 in 41% (7/17) pts. and amplification of CKS1B gene in 63% (12/19) pts. Overall response (OR) was 83% (0% CR, 29% VGPR, 54% PR). OR was not significantly higher in pts. with or without cytogenetic findings for all aberration types. There were no difference when compared OS, TTP, PFS and DOR for groups with or without each aberration except deletion of RB gene or amplification of CKS1B: average OS was 10,2 (SD=3,4) months vs. 6,6 (SD=2,2) months in patients with vs. without the RB deletion and 7,1 (SD=3,1) vs. 10,0(SD=3,8) months for amplification of CKS1B. Conclusion: Despite of the observed trends in patients with CKS1B amplification or deletion of RB gene, we have found no significant difference when compared groups with or without of each aberration for TTP, DOR, PFS, OS and response rate. This should have been caused by small size of our sample. It is still possible that Thalidomide antagonizes the negative prognostic value of some cytogenetic findings in MM.

Česky

Význam delece RB a p53, translokace t(4;14) a amplifikace 1q21, negativních prognostických faktorů při konvenční terapii, u pacientů s mnohočetným myelomem léčených thalidomidem.

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

MSM0021622415, záměr

Název: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární podstata buněčných a tkáňových regulací

Citovat

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ a Roman HÁJEK. Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide. In Haematologica. Vol. 92(s2). Pavia (Italy): Ferrata-Storti foundation, 2007, s. 170. ISSN 0390-6078.

@inproceedings{726717,
   author = {Zaoralová, Romana and Grešliková, Henrieta and Filková, Hana and Němec, Pavel and Kuglík, Petr and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
   address = {Pavia (Italy)},
   booktitle = {Haematologica},
   edition = {Vol. 92(s2)},
   keywords = {Multiple myeloma; thalidomide; cIg FISH},
   language = {eng},
   location = {Pavia (Italy)},
   pages = {170-170},
   publisher = {Ferrata-Storti foundation},
   title = {Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide},
   year = {2007}
}

TY  - JOUR
ID  - 726717
AU  - Zaoralová, Romana - Grešliková, Henrieta - Filková, Hana - Němec, Pavel - Kuglík, Petr - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Křivanová, Andrea - Krejčí, Marta - Hájek, Roman
PY  - 2007
TI  - Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide
PB  - Ferrata-Storti foundation
CY  - Pavia (Italy)
KW  - Multiple myeloma
KW  - thalidomide
KW  - cIg FISH
N2  - The aim of this prospective study is to investigate if Thalidomide is able to antagonize the impact of cytogenetic negative prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of 13q14 (RB), deletion of 17p13 (p53), amplification of CKS1B gene (1q21) and translocation t(4;14). Material and Methods: For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labelling methodology. This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-k or anti-l) and to detect chromosomal abnormalities by fluorescence in situ hybridization (cIg-FISH). Overall characteristics of up-to-date set of 24 patients (pts.): median age 65,0 years (range 48,3-83,3). 66% (16/24 pts.) in stage IIIA, 29% (7/24 pts.) in stage IIA and 1 patient in IIIB. 75% (16/24 pts.) were in first relapse; the others were in second relapse. Preliminary Results: Cytogenetic findings: Deletion of 13q14 was detected in 62% (13/21) pts., t(4;14) in 66% (14/21) pts., deletion of 17p13 in 41% (7/17) pts. and amplification of CKS1B gene in 63% (12/19) pts. Overall response (OR) was 83% (0% CR, 29% VGPR, 54% PR). OR was not significantly higher in pts. with or without cytogenetic findings for all aberration types. There were no difference when compared OS, TTP, PFS and DOR for groups with or without each aberration except deletion of RB gene or amplification of CKS1B: average OS was 10,2 (SD=3,4) months vs. 6,6 (SD=2,2) months in patients with vs. without the RB deletion and 7,1 (SD=3,1) vs. 10,0(SD=3,8) months for amplification of CKS1B. Conclusion: Despite of the observed trends in patients with CKS1B amplification or deletion of RB gene, we have found no significant difference when compared groups with or without of each aberration for TTP, DOR, PFS, OS and response rate. This should have been caused by small size of our sample. It is still possible that Thalidomide antagonizes the negative prognostic value of some cytogenetic findings in MM.
ER  -

ZAORALOVÁ, Romana, Henrieta GREŠLIKOVÁ, Hana FILKOVÁ, Pavel NĚMEC, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ a Roman HÁJEK. Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide. In \textit{Haematologica}. Vol. 92(s2). Pavia (Italy): Ferrata-Storti foundation, 2007, s.~170. ISSN~0390-6078.

Podrobný výpis o publikaci